You are here: Home » Companies » News
Business Standard

Gland Pharma inks pact to supply 252 mn doses of Sputnik V Covid vaccine

The production is expected to commence from the third quarter of 2021 for estimated delivery starting from the fourth quarter of 2021

Topics
Gland Pharma | Coronavirus

Press Trust of India  |  New Delhi 

Sputnik Covid-19 vaccine

Drug firm on Tuesday said it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to supply up to 252 million doses of Sputnik V COVID-19 vaccine.

The company "will be leveraging its manufacturing capabilities for the production of Sputnik V COVID-19 vaccine," said in a regulatory filing.

The agreement will see the company utilising its Drug Substance and Drug Product facilities at its sites in Hyderabad. The production is expected to commence from the third quarter of 2021 for estimated delivery starting from the fourth quarter of 2021, it added.

"Under the terms of the agreement, will first undertake technology transfer of the drug substance to its manufacturing facilities," the filing said.

After successful technology transfer, the company will then undertake manufacturing of drug substance and drug product filling into vials under aseptic conditions, it added.

The company's expertise in manufacturing sterile injectables at a significant scale will support in establishing a stable supply of COVID-19 vaccine, Gland Pharma said.

Earlier in November 2020,Russia's sovereign wealth fund had said in a statement that RDIF and pharma firm Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19.

Pharma major Dr Reddy's Laboratories in February this year had said that it has approachedDrugs Controller General of India (DCGI) for emergency use authorisation (EUA) for COVID-19 vaccine Sputnik V.

Shares of Gland Pharma closed at Rs2,718.65per scrip on BSE, up 6.95 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, March 16 2021. 17:32 IST
RECOMMENDED FOR YOU
.